Creo Medical Receives FDA Clearance for Hemostasis Device

UK-based Creo Medical received 510(k) clearance from the FDA for its HS1 hemostasis device for stopping bleeding during certain treatments.

The single use device will be used with Creo's CROMA Advanced Energy Platform. It offers high precision for endoscopic use and combining injection therapy and can be used to stop bleeding during treatments for peptic ulcers and other conditions.

Creo’s CROMA electrosurgical platform enables precise endoscopic surgery with miniature endoscopic instruments that cut, coagulate and ablate soft tissue.